Exp Ther Med. 2015 May;9(5):1763-1767. doi: 10.3892/etm.2015.2324. Epub 2015 Mar 02.

Analysis of the clinical and molecular characteristics of a child with achondroplasia: A case report.

Experimental and therapeutic medicine

Jingfang Liu, Xulei Tang, Jianguo Cheng, Liting Wang, Xiaomei Yang, Yan Wang

PMID: 26136890 PMCID: PMC4471706 DOI: 10.3892/etm.2015.2324

Abstract

Achondroplasia (ACH) is a hereditary dwarfism caused by the disturbed proliferation and differentiation of growth plate chondrocytes, followed by impaired endochondral bone growth. ACH is caused by mutations in the gene encoding the transmembrane receptor, fibroblast growth factor receptor 3 (FGFR3). In total, >90% of patients with ACH have a G1138A mutation in the transmembrane domain of the FGFR3 gene. Patients with ACH usually have no growth hormone (GH) deficiency. The current study presents the case of a four-year-old male with clinical manifestations suggestive of ACH, including a large head, prominent forehead, short upper arms and legs, and short hands with fingers assuming a trident position. The patient showed normal responses to GH provocation tests with L-dopa (peak GH concentration, 42.38 ng/ml) and insulin (peak GH concentration, 23.29 ng/ml during hypoglycemia), but a blunted response to a GH provocation test with arginine (peak GH concentration, 7.31 ng/ml). Furthermore, the GH concentration during exercise was low (4.8 ng/ml). Magnetic resonance imaging revealed a decreased pituitary volume. Thyroid function tests and the levels of sex hormones (follicle stimulating hormone, luteinizing hormone, estradiol, prolactin and progesterone), cortisol and adrenocorticotropic hormone were normal. A heterozygous G1138A mutation within the FGFR3 gene was detected, confirming the diagnosis of ACH. Thus, recombinant human GH therapy (0.1 IU/kg/day) was initiated. At the six-month follow-up, the height, arm span-to-height ratio and lower limb length-to-height ratio of the patient had increased, while the head circumference had decreased. The present results corroborate the finding that the G1138A mutation within FGFR3 is the most common ACH-causing mutation in different populations. GH may be beneficial in the treatment of short stature in ACH patients with subnormal GH secretion.

Keywords: achondroplasia; fibroblast growth factor receptor 3; growth hormone; mutation

References

1. J Med Genet. 1986 Aug;23(4):328-32 - PubMed
2. Chin Med J (Engl). 2007 Jun 5;120(11):1017-9 - PubMed
3. Genet Test Mol Biomarkers. 2012 Apr;16(4):297-301 - PubMed
4. Nat Genet. 1996 Jun;13(2):233-7 - PubMed
5. Eur J Endocrinol. 1998 Mar;138(3):275-80 - PubMed
6. Am J Hum Genet. 1998 Sep;63(3):711-6 - PubMed
7. EMBO J. 1996 Feb 1;15(3):520-7 - PubMed
8. Lancet. 2007 Jul 14;370(9582):162-72 - PubMed
9. Int J Biol Sci. 2010 Jun 15;6(4):327-32 - PubMed
10. Orphanet J Rare Dis. 2012 Aug 22;7:55 - PubMed
11. Horm Res. 2000;53 Suppl 3:53-6 - PubMed
12. Hum Mol Genet. 1994 May;3(5):787-92 - PubMed
13. Eur J Pediatr. 1995 Mar;154(3):215-9 - PubMed
14. Immunol Cell Biol. 1995 Dec;73(6):584-9 - PubMed
15. Hum Mol Genet. 2009 Jan 15;18(2):227-40 - PubMed
16. PLoS One. 2012;7(10):e46678 - PubMed
17. J Pediatr Endocrinol. 1993 Jan-Mar;6(1):45-52 - PubMed
18. Nature. 1994 Sep 15;371(6494):252-4 - PubMed
19. Turk J Pediatr. 2003 Apr-Jun;45(2):99-101 - PubMed
20. Mol Cell Biol. 1996 Mar;16(3):977-89 - PubMed
21. Calif Med. 1966 Aug;105(2):104-10 - PubMed
22. Endocr J. 2003 Feb;50(1):69-75 - PubMed
23. Cell. 1994 Jul 29;78(2):335-42 - PubMed
24. Pediatr Res. 1999 Oct;46(4):435-9 - PubMed

Publication Types

• Journal Article